Determine the necessary mass, volume, or concentration for preparing a solution.
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
SKU | Size | Availability | Price | Qty |
---|---|---|---|---|
Z129382-25mg | 25mg | In stock | $9.90 | |
Z129382-100mg | 100mg | In stock | $14.90 | |
Z129382-1g | 1g | In stock | $28.90 | |
Z129382-5g | 5g | In stock | $98.90 | |
Z129382-25g | 25g | In stock | $444.90 |
Highly potent bisphosphonate. FPP synthase inhibitor.
Synonyms | Zoledronic acid|118072-93-8|Zoledronate|Zometa|Reclast|Aclasta|(1-Hydroxy-2-(1H-imidazol-1-yl)ethane-1,1-diyl)diphosphonic acid|CGP 42446|(1-Hydroxy-2-imidazol-1-ylethylidene)diphosphonic acid|Zoledronic Acid Anhydrous|C5H10N2O7P2|Anhydrous Zoledronic Aci |
---|---|
Specifications & Purity | ≥99% |
Storage Temp | Store at -20°C |
Shipped In | Dry ice |
Grade | Moligand™ |
Action Type | INHIBITOR |
Mechanism of action | Farnesyl diphosphate synthase inhibitor |
ALogP | -4.3 |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Pubchem Sid | 488184180 |
---|---|
Pubchem Sid Url | https://pubchem.ncbi.nlm.nih.gov/substance/488184180 |
IUPAC Name | (1-hydroxy-2-imidazol-1-yl-1-phosphonoethyl)phosphonic acid |
INCHI | InChI=1S/C5H10N2O7P2/c8-5(15(9,10)11,16(12,13)14)3-7-2-1-6-4-7/h1-2,4,8H,3H2,(H2,9,10,11)(H2,12,13,14) |
InChi Key | XRASPMIURGNCCH-UHFFFAOYSA-N |
Canonical SMILES | C1=CN(C=N1)CC(O)(P(=O)(O)O)P(=O)(O)O |
Isomeric SMILES | C1=CN(C=N1)CC(O)(P(=O)(O)O)P(=O)(O)O |
PubChem CID | 68740 |
Molecular Weight | 272.09 |
ChEMBL Ligand | CHEMBL924 |
---|---|
DrugBank Ligand | DB00399 |
Wikipedia | Zoledronate |
CAS Registry No. | 118072-93-8 |
PubChem CID | 68740 |
ChEBI | CHEBI:46557 |
RCSB PDB Ligand | ZOL |
PEP | zoledronic acid |
Immunopaedia Search | zoledronic acid |
DrugCentral Ligand | 2868 |
PubChem SID | 488184180 |
Enter Lot Number to search for COA:
To view the certificate results,please click on a Lot number.For Lot numbers from past orders,please use our order status section
Lot Number | Certificate Type | Date | Item |
---|---|---|---|
H2406230 | Certificate of Analysis | Mar 02, 2024 | Z129382 |
G23221028 | Certificate of Analysis | Jul 07, 2023 | Z129382 |
H2429022 | Certificate of Analysis | Jul 07, 2023 | Z129382 |
G23221042 | Certificate of Analysis | Jul 07, 2023 | Z129382 |
G23221041 | Certificate of Analysis | Jul 07, 2023 | Z129382 |
G23221040 | Certificate of Analysis | Jul 07, 2023 | Z129382 |
G23221038 | Certificate of Analysis | Jul 07, 2023 | Z129382 |
G23221037 | Certificate of Analysis | Jul 07, 2023 | Z129382 |
G23221034 | Certificate of Analysis | Jul 07, 2023 | Z129382 |
G23221033 | Certificate of Analysis | Jul 07, 2023 | Z129382 |
G23221017 | Certificate of Analysis | Jul 07, 2023 | Z129382 |
C2415131 | Certificate of Analysis | Jul 07, 2023 | Z129382 |
C2130027 | Certificate of Analysis | Jan 12, 2023 | Z129382 |
C2130026 | Certificate of Analysis | Jan 12, 2023 | Z129382 |
C2130024 | Certificate of Analysis | Jan 12, 2023 | Z129382 |
D1912082 | Certificate of Analysis | Dec 06, 2022 | Z129382 |
F2230307 | Certificate of Analysis | Jul 04, 2022 | Z129382 |
F2215113 | Certificate of Analysis | Jun 23, 2022 | Z129382 |
E2312259 | Certificate of Analysis | Jun 23, 2022 | Z129382 |
C2011020 | Certificate of Analysis | Jan 27, 2022 | Z129382 |
Solubility | DMSO 0.004 mg/mL Water <1 mg/mL Ethanol <1 mg/mL |
---|
Pictogram(s) | GHS07 |
---|---|
Signal | Warning |
Hazard Statements | H319:Causes serious eye irritation H317:May cause an allergic skin reaction |
Precautionary Statements | P261:Avoid breathing dust/fume/gas/mist/vapors/spray. P305+P351+P338:IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present and easy to do - continue rinsing. P280:Wear protective gloves/protective clothing/eye protection/face protection. P302+P352:IF ON SKIN: wash with plenty of water. P321:Specific treatment (see ... on this label). P501:Dispose of contents/container to ... P272:Contaminated work clothing should not be allowed out of the workplace. P333+P313:IF SKIN irritation or rash occurs: Get medical advice/attention. P362+P364:Take off contaminated clothing and wash it before reuse. P264+P265:Wash hands [and …] thoroughly after handling. Do not touch eyes. P337+P317:If eye irritation persists: Get medical help. |
1. Lu H et al.. (2021) B7-H3 confers resistance to V?9Vd2 T cell-mediated cytotoxicity in human colon cancer cells via the STAT3/ULBP2 axis.. Cancer Immunol Immunother, 70 (5): (1213-1226). [PMID:33119798] |
2. Lu H et al.. (2020) B7-H3 inhibits the IFN-?-dependent cytotoxicity of V?9Vd2 T cells against colon cancer cells.. Oncoimmunology, 9 (1748991). [PMID:32363121] |